June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Methicillin-resistant Staphylococcus aureus (MRSA) keratitis: An analysis of outcomes of cases treated initially with vancomycin versus cases treated with fluoroquinolone drops
Author Affiliations & Notes
  • Sarah Atta
    Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Asad Farooq Durrani
    Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
    Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States
  • Amar Bhat
    Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Eric G Romanowski
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
  • Robert M Q Shanks
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
  • Alex Mammen
    Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
  • Deepinder K Dhaliwal
    Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
  • Regis P Kowalski
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
  • Vishal Jhanji
    Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Sarah Atta, None; Asad Durrani, None; Amar Bhat, None; Eric Romanowski, None; Robert Shanks, None; Alex Mammen, None; Deepinder Dhaliwal, None; Regis Kowalski, None; Vishal Jhanji, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4887. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarah Atta, Asad Farooq Durrani, Amar Bhat, Eric G Romanowski, Robert M Q Shanks, Alex Mammen, Deepinder K Dhaliwal, Regis P Kowalski, Vishal Jhanji; Methicillin-resistant Staphylococcus aureus (MRSA) keratitis: An analysis of outcomes of cases treated initially with vancomycin versus cases treated with fluoroquinolone drops. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4887.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Methicillin-resistant Staphylococcus aureus (MRSA) can cause fulminant keratitis that quickly threatens vision in patients with healthy corneas. Prompt recognition and appropriate antibiotic selection is required. Often these patients are treated with vancomycin, however, patients with MRSA keratitis can respond to fluoroquinolones. Given increasing concerns regarding antibiotic resistance, this study sought to determine if fluoroquinolone treatment was non-inferior to vancomycin treatment in cases of MRSA keratitis.

Methods : 52 culture-proven cases (48 subjects) of MRSA keratitis from 2008-2019 at the University of Pittsburgh Medical Center were identified and retrospectively reviewed for ocular and systemic risk factors, treatment modalities, outcomes, as well as antimicrobial sensitivity and resistance data.

Results : Two groups were identified: those treated initially with a fluoroquinolone (n=36 eyes) and those treated initially with vancomycin (n=16 eyes). Mean age in the fluoroquinolone group was 66.83±18.87 with mean follow-up time 370.72±531.59 days. Mean age in the vancomycin group was 63.56±21.25 with mean follow-up 239.56±267.09 days. Mean logmar visual acuity (VA) at presentation in the fluoroquinolone group was 1.59±0.68 compared to 1.94±0.93 in the vancomycin group (p=0.172). Final logmar VA was 1.16±0.97 in the fluoroquinolone group compared to 1.36±1.06 (p=.540). Mean treatment duration in the fluoroquinolone group was 89.26±85.93 compared to 117±176.90 in the vancomycin group. There was no statistically significant difference in the presence of hypopyon (p=0.356), need for adjunctive treatment (p=0.106), i.e. procedures such as tarsorrhaphy (p=0.662), debridement (p=1.00), penetrating keratoplasty (p=1.00), or enucleation (p=0.308).

Conclusions : Despite treatment with a fluoroquinolone in many cases, presenting characteristics and outcomes were comparable to those initially treated with vancomycin. This suggests the virulence of MRSA within ocular structures may be decreased as many cases of fluoroquinolone “resistant” MRSA by laboratory testing responded to fluoroquinolone therapy. Given the concern for antibiotic resistance as well as corneal toxicity from fortified vancomycin, fluoroquinolone therapy for MRSA keratitis may be a reasonable initial treatment option with close monitoring.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×